Respiro Diagnostics develops non-invasive breath-based diagnostic tests for early detection of lung cancer and other respiratory diseases.
Respiro Diagnostics has raised $1.3M in total funding. The most recent round was Pre-Seed. The last funding was announced in July 2026.
Respiro Diagnostics's investors include SFC Capital, Amadeus Capital Partners, Innovate UK, The Francis Crick Institute, Conception X.
Respiro Diagnostics is headquartered in Leeds, United Kingdom.
Respiro Diagnostics develops non-invasive breath-based diagnostic tests for early detection of lung cancer and other respiratory diseases.
Respiro Diagnostics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Respiro Diagnostics — Funding & Investors." VCBacked, July 8, 2026, https://www.vcbacked.co/company/respiro-diagnostics. Accessed September 14, 2026.
VCBacked. (2026). Respiro Diagnostics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/respiro-diagnostics
{{cite web |title=Respiro Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/respiro-diagnostics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated